0.95%
4.92%
0.95%
-4.48%
-25.93%
-46.93%
-24.53%
AI Spotlight on MEDI
Company Description
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally.It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use.The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.
In addition, it distributes and sells third party medical equipment.The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Market Data
| Last Price | 160 |
| Change Percentage | 0.95% |
| Open | 159.5 |
| Previous Close | 158.5 |
| Market Cap ( Millions) | 2930 |
| Volume | 12989 |
| Year High | 227 |
| Year Low | 130 |
| M A 50 | 150.06 |
| M A 200 | 166.51 |
Financial Ratios
| FCF Yield | 3.51% |
| Dividend Yield | 2.81% |
| ROE | 25.15% |
| Debt / Equity | 1.84% |
| Net Debt / EBIDTA | -76.97% |
| Price To Book | 7.23 |
| Price Earnings Ratio | 28.83 |
| Price To FCF | 28.45 |
| Price To sales | 5.36 |
| EV / EBITDA | 18.05 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Own Products
Expected Growth : 5 %
What the company do ?
Own Products from Medistim ASA refers to the company's proprietary medical devices and systems for cardiac and vascular procedures, including ultrasound and imaging solutions.
Why we expect these perspectives ?
Strong demand for cardiovascular procedures, increasing adoption of minimally invasive surgeries, and Medistim's innovative products such as the TEE probe and ChillX system drive growth. Expanding distribution channels, strategic partnerships, and investments in R&D further support the 5% growth rate.
Segment n°2 -> Third Party Products
Expected Growth : 3 %
What the company do ?
Third Party Products from Medistim ASA refers to medical devices and solutions from other manufacturers that are distributed and sold by Medistim ASA, enhancing their product portfolio.
Why we expect these perspectives ?
Strong demand for cardiovascular procedures, increasing adoption of minimally invasive surgeries, and strategic partnerships with hospitals and clinics drive growth for Medistim ASA's Third Party Products. Additionally, expanding product offerings and geographic presence contribute to the segment's growth.
Medistim Asa Products
| Product Range | What is it ? |
|---|---|
| TEEprobe | A transesophageal echocardiography (TEE) probe designed for intraoperative and intensive care unit (ICU) use |
| QPULSA | A non-invasive, ultrasound-based cardiac output monitor |
| LlowFlow | A low-flow perfusion system for cardiopulmonary bypass surgery |
| QPULSA Verifi | A non-invasive, ultrasound-based cardiac output monitor with advanced analytics |
Medistim ASA's Porter Forces
Threat Of Substitutes
Medistim ASA operates in the medical technology industry, where substitutes are limited. However, the company's products may face competition from alternative treatments or procedures.
Bargaining Power Of Customers
Medistim ASA's customers are primarily hospitals and healthcare providers, who have limited bargaining power due to the specialized nature of the company's products.
Bargaining Power Of Suppliers
Medistim ASA relies on a few key suppliers for components and materials, which gives them some bargaining power. However, the company's strong relationships with suppliers mitigate this risk.
Threat Of New Entrants
The medical technology industry has high barriers to entry, including regulatory hurdles and significant R&D investments. This limits the threat of new entrants.
Intensity Of Rivalry
The medical technology industry is highly competitive, with several established players competing for market share. Medistim ASA faces intense rivalry from companies such as Abbott and Medtronic.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.25% |
| Debt Cost | 3.95% |
| Equity Weight | 95.75% |
| Equity Cost | 7.73% |
| WACC | 7.57% |
| Leverage | 4.43% |
Medistim ASA : Quality Control
Medistim ASA passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| IBAB.BR | Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and … |
| REG1V.HE | Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
| LFWD | ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Revenio
A-Score
1-Year Total Return ->
🥈
Ion Beam Applications
A-Score
1-Year Total Return ->
🥉
CellaVision
A-Score
1-Year Total Return ->
4
Medistim
A-Score
1-Year Total Return ->
5
Xvivo Perfusion
A-Score
1-Year Total Return ->
6
